Senti Biosciences (Senti Biosciences) EBIT : $-72.55 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Senti Biosciences EBIT?

Senti Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-16.30 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-72.55 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Senti Biosciences's annualized ROC % for the quarter that ended in Mar. 2024 was -84.30%. Senti Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -130.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Senti Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -280.77%.

Senti Biosciences EBIT Historical Data

The historical data trend for Senti Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senti Biosciences EBIT Chart

Senti Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-24.69

-40.45

-62.08

-66.77

Senti Biosciences Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial								-14.96	-19.64	-18.19	-18.43	-16.30

Competitive Comparison of Senti Biosciences's EBIT

For the Biotechnology subindustry, Senti Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Senti Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senti Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Senti Biosciences's EV-to-EBIT falls into.

Senti Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.55 Mil.

Senti Biosciences (NAS:SNTI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Senti Biosciences's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-65.204 * ( 1 - 0% )	/	( (78.744	+	75.947)	/ 2 )
=	-65.204	/	77.3455
=	-84.30 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	119.484	-	4.814	-	( 35.926	-	max(0, 12.672	-	71.2	+	35.926	))
=	78.744

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	102.185	-	2.515	-	( 23.723	-	max(0, 9.609	-	55.666	+	23.723	))
=	75.947

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Senti Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-65.204	/	( ( (41.612 + max(9.138, 0))	+	(40.151 + max(8.765, 0)) )	/	2 )
=	-65.204	/	( ( 50.75	+	48.916 )	/	2 )
=	-65.204	/	49.833
=	-130.85 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.112	+	0	+	17.57)	-	(4.814	+	0.989	+	2.741)
=	9.138

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.076	+	0	+	14.02)	-	(2.515	+	0.862	+	1.954)
=	8.765

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Senti Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-72.548	/	25.839
	=	-280.77 %

Senti Biosciences EBIT Related Terms

Thank you for viewing the detailed overview of Senti Biosciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Senti Biosciences (Senti Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Senti Biosciences Inc (NAS:SNTI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080

Website

https://www.sentibio.com

Senti Biosciences Inc is a preclinical biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.

Executives

Kanya Rajangam	officer: Chief Medical & Devt. Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Aktiengesellschaft Bayer	10 percent owner	BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368
Susan D Berland	director	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy K Lu	director, officer: CEO and President	SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
James J. Collins	director	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bayer World Investments B.v.	10 percent owner	ENERGIEWEG 1, MIJDRECHT P7 3641
Deborah Knobelman	officer: Chief Financial Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Herberts Curt A. Iii	officer: Chief Operating Officer	501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Brenda Cooperstone	director	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Philip J Lee	officer: Chief Technology Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Edward T Mathers	director	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Nea 15 Gp, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093